Related Experiment Videos
Release of immunoreactive met-enkephalin by intraventricular beta-endorphin in anesthetized rats
Abstract:
The release of immunoreactive met-enkephalin and leu-enkephalin from the spinal cord by intraventricular injection of different doses of beta-endorphin was studied using the intrathecal perfusion technique. The intraventricular beta-endorphin elicited the release of immunoreactive met-enkephalin from the spinal cord in a dose dependent manner. Immunoreactive leu-enkephalin in the spinal perfusate was not increased after intraventricular beta-endorphin injection. Both immunoreactive met-enkephalin and leu-enkephalin in the spinal cord were not changed by low doses (2-6 micrograms) of beta-endorphin but were increased markedly by 60-70% after high doses of beta-endorphin (32-64 micrograms). It is likely that the biosynthesis of enkephalins was also increased after intraventricular beta-endorphin injection. Intraventricular naloxone, 30 micrograms did not induce any release of immunoreactive met-enkephalin from the spinal cord and did not block the release of immunoreactive met-enkephalin induced by intraventricular beta-endorphin, 15 micrograms.
Insights
High doses of beta-endorphin trigger the release of met-enkephalin from the spinal cord. This peptide release is dose-dependent and may also involve increased enkephalin biosynthesis.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Opioid peptides, including beta-endorphin and enkephalins (met-enkephalin and leu-enkephalin), play crucial roles in pain modulation and other central nervous system functions.
- The interaction between different endogenous opioids within the spinal cord is complex and not fully understood.
Purpose of the Study:
- To investigate the effect of intraventricular beta-endorphin administration on the release of immunoreactive met-enkephalin and leu-enkephalin from the spinal cord.
- To determine the dose-dependency of beta-endorphin's effect on enkephalin release.
- To explore the potential involvement of naloxone in modulating beta-endorphin-induced enkephalin release.
Main Methods:
- Intrathecal perfusion technique was employed to collect perfusate from the spinal cord.
- Intraventricular injections of varying doses of beta-endorphin were administered.
- Concentrations of immunoreactive met-enkephalin and leu-enkephalin in spinal perfusate and tissue were measured.
- The effect of intraventricular naloxone on enkephalin release was also assessed.
Main Results:
- Intraventricular beta-endorphin administration dose-dependently increased the release of immunoreactive met-enkephalin from the spinal cord.
- Immunoreactive leu-enkephalin release was not significantly affected by intraventricular beta-endorphin.
- Low doses of beta-endorphin (2-6 µg) did not alter spinal enkephalin levels, while high doses (32-64 µg) significantly increased both met-enkephalin and leu-enkephalin in the spinal cord.
- Intraventricular naloxone (30 µg) did not induce met-enkephalin release nor block beta-endorphin-induced met-enkephalin release.
Conclusions:
- Beta-endorphin, particularly at high doses, stimulates the release of met-enkephalin from the spinal cord.
- The observed increase in spinal enkephalins suggests a potential enhancement of enkephalin biosynthesis following beta-endorphin administration.
- Naloxone does not appear to mediate or antagonize the release of met-enkephalin induced by beta-endorphin in this experimental model.